Max India Ltd · NSE:MAXIND
Max India — Investor Presentation (January 2008)
44 slides from Max India's investor presentation, January 2008
Slide 1: Max India Limited Investor Presentation
Max India Limited Investor Presentation This presentation is a compilation of unaudited financial and other information. This may also contain statements that are forward looking. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual r
Slide 2: Max India – An Introduction
Max India – An Introduction Max India Limited is a multi-business corporate, driven by the spirit of Enterprise, focused on Knowledge, People and Service oriented businesses of Life Insurance, Healthcare and Clinical Research. Max’s other businesses are Speciality Plastic Products for the packaging
Slide 3: Max India – Key Highlights
Max India – Key Highlights n Promoted by Mr. Analjit Singh a prominent Indian industrialist, in 1988 n Amongst one of the leading conglomerates in India Life Insurance – 74:26 JV with New York Life… 5.5% Market Share amongst Private Players Healthcare – 70% Owned… 8 Healthcare Facilities with 77
Slide 4: Max India – Key Highlights
Max India – Key Highlights Consolidated Performance Summary US$ Mn Y-o-Y Y-o-Y Particulars 9M FY08 9M FY07 2006-07 2005-06 Grow th Grow th Shareholders Funds 398.4 155.6 156% 152.6 162.4 -6% Borrow ings** 96.3 84.2 14% 97.3 63.3 54% Net Fixed Assets 175.4 141.3 24% 159.1 113.1 41% Investments 1171.3
Slide 5: Max India – Board of Directors
Max India – Board of Directors Director Profile Mr. Analjit Singh Mr. Singh has been the driving force behind Max Group’s sustained growth and success since the early 80’s. Mr. Singh a prominent industrialist is an alumnus of Doon School; University of Delhi, and the Graduate Executive Chairman Scho
Slide 6: Max New York Life Insurance
Max New York Life Insurance www.maxnewyorklife.com 6
Slide 7: India's Life Insurance Industry is Witnessing Rapid Growth
India’s Life Insurance Industry is Witnessing Rapid Growth Strong Growth driven by… n Low Penetration Level n Increasing Per Capita Income n Strong GDP Growth n Absence of Social Security Cover n Increasing Awareness n Better Distribution n Availability of Multiple Products n Increased Life Expectan
Slide 8: Max New York Life Insurance [MNYL]
Max New York Life Insurance [ MNYL] n Joint Venture between Max India and New York Life International [ NYL ] n NYL, one of Fortune 100 companies, is the oldest mutual life insurance company in the US with over $200 billion in assets under management n Max India and NYL jointly drive the growth stra
Slide 9: MNYL road map to becoming India's most admired Life Insurance Company
MNYL road map to becoming India’s most admired Life Insurance Company Key Public Messages VISION Become the most admired Life Insurance Company in India A trusted life insurance specialist Part of top quartile new Life Insurance Companies Customer centric National Player Financially respon
Slide 10: MNYL – Board of Directors
MNYL – Board of Directors Mr. Analjit Singh Chairman Mr. B Anantharaman Joint Managing Director, Max India Limited Dr. S. S. Baijal Mr. N. C. Singhal Mr. Rajesh Khanna Managing Director, Warburg Pincus Mr. Anuroop Singh Mr. John Harrison Vice Chairman and CEO, Asia Region, NYL Mr. Ravi Akhoury Chair
Slide 11: Protection Oriented, Longer Tenor Life Insurance
Protection Oriented, Longer Tenor Life Insurance PROPORTION OF Tenure Age of Insured PRODUCT TYPE POLICIES (%, by (Years) (Years) number) WHOLE LIFE 21 40 36 ENDOWMENT 18 22 28 TERM 4 23 35 DEFERRED 1 17 41 ANNUITY MONEY BACK 13 14 34 UNIT LINKED 43 22 36 25 34 As on Dec 31, 2007 MNYL Average MNYL A
Slide 12: Established Ourselves amongst the Leading Agency Sales Force
Established Ourselves amongst the Leading Agency Sales Force Adjusted Single premium New Business Apr – Sep 2007 Agents Premium per Agent* ($) Cases per Agent* (Agency) (US$ Mn) 336 2,56,000 219 0.44 334 2,50,000 223 0.67 106 1,25,000 141 0.31 96 1,25,000 129 0.29 96 Rank 5 25,802 617 Rank 1 1.17 Ra
Slide 13: MNYL – Key Highlights
MNYL – Key Highlights 9 Mn Policyholders AFYP US$ 2 Bn by 2011 by 2011 * 200,000 Agents by 2011 600 Sales Offices, 400 locations by 2011 US$ 1 = INR 39.50 13
Slide 14: MNYL – Key Highlights
MNYL – Key Highlights * * Conservation Ratio = Renewal Premium for the current period/(First Year+Renewal Premium for the previous period) 14 US$ 1 = INR 39.50
Slide 15: Strengths and Growth Strategy
Strengths and Growth Strategy Strengths n One of India's leading private providers of life insurance with a well recognized brand name n Strong and extensive distribution channels with 233 field offices across 155 locations and over 30,000 exclusive sales agents n Partnership with 18 banks, current
Slide 16: Max Healthcare
Max Healthcare www.maxhealthcare.in 16
Slide 17: Indian Healthcare
Indian Healthcare Key Drivers n Shift to Lifestyle-Related diseases Indian Healthcare industry expected to grow at a 15% n Growing Middle class CAGR till 2012 to contribute 6.1% of GDP n Changing Spending Patterns n Infrastructure Needs n Health Insurance n Medical Value Travel Healthcare Industry 2
Slide 18: Max Healthcare Model
Max Healthcare Model Heart and Vascular Neurosciences n Heart and Vascular Institute Joint Replacement and Tertiary Orthopaedics n Super Speciality Hospital Obstetrics and Gynaecology Paediatrics Surgery and inpatient facilities n Hospitals – 4 High-end Diagnostics: Secondary MRI, CT n
Slide 19: Max Healthcare – Board of Directors
Max Healthcare – Board of Directors Mr. Analjit Singh Chairman and Managing Director Mr. B Anantharaman Joint Managing Director, Max India Limited Dr. Ashok Seth Mr. KK Mathur Dr. RP Soonawala Mr. Aman Mehta Mr. Anuroop Singh Mr. Rajesh Khanna Warburg Pincus Mr. Leo Puri Warburg Pincus 19
Slide 20: Max Healthcare – Key Highlights
Max Healthcare – Key Highlights Fact Sheet Shareholding pattern Healthcare Facilities 8 Number of Outstanding Shares 237,094,548 Physicians 1,250* Max India Limited 70.1% Other Support Staff 2,600 Patient Base Over 530,000 Patient Transactions Over 140,000 pm Beds 770 ICU Beds 190 OTs 19 Cathlabs 3
Slide 21: Max Healthcare – Key Highlights
Max Healthcare – Key Highlights Average Operational Beds & US$ 1 = INR 39.50 21
Slide 22: Max Healthcare – Key Highlights
Max Healthcare – Key Highlights 22 US$ 1 = INR 39.50
Slide 23: Current Facilities
Current Facilities TERTIARY CARE MAX HOSPITALS OPERATIONAL AT SAKET [South Delhi]… MAX HEART & VASCULAR INSTITUTE MAX SUPER SPECIALITY HOSPITAL (December 2004) (May 2006) n 200 patient beds n 188 beds (including 63 critical care beds) n 3 OTs, 2 Cardiac Catheterization Labs n Post Surgery Critical C
Slide 24: Current Facilities
Current Facilities SECONDARY CARE MAX HOSPITALS OPERATIONAL AT… PITAMPURA NOIDA PATPARGANJ (February 2002) (August 2002) (May 2005) (North Delhi) (Suburb) (East Delhi) 90 inpatient beds 39 inpatient beds 147 inpatient beds 2 OT 2 OT 3 OT Lithotripsy Mother and Child care Mother and
Slide 25: Current Facilities
Current Facilities SPECIALITY CENTRES – PANCHSHEEL [South Delhi] OPTHALMOLOGY AND DENTAL CARE SPECIALIST CONSULTS AND (November 2005) HIGH-END DIAGNOSTICS (August 2006) Lasik, OPD and Diagnostics Dental – 3 chambers GP and Specialist Consults Support Services and Offices Full Diagnostics (
Slide 26: New Facility
New Facility MAX HOSPITAL – GURGAON [Suburb] n 108 Inpatient beds with 2 OTs n Tower Specialties Include: Ophthalmology (Anterior and Posterior) Woman and Child (including Infertility) Orthopaedics Nephrology and Urology Plastic and Reconstructive Surgeries General and Minimally Invasive
Slide 27: Second Phase of Expansion
Second Phase of Expansion National Capital Region Max Balaji Hospital – Patparganj Max Hospital – Shalimar Bagh Tertiary Care Tertiary Care / Multi-Speciality n Around 270 inpatient beds with 6 OTs and 1 n Potential Bed Capacity around 300 Beds Cathlab – Launch expected by August 2009 n Expected lau
Slide 28: Max Healthcare Project Cost and Funding
Max Healthcare Project Cost and Funding n Max India Equity Current – $42 Mn Capital n Warburg Pincus – $35 Mn n IFC, Washington – $13 Mn US$ 95 million n Other Foreign Investors – $5 Mn Preference Project Cost Capital n IFC, Washington US$ 239 million US$ 63 million Debt n Indian Banks and Financi
Slide 29: Strengths and Growth Strategy
Strengths and Growth Strategy Strengths… n Comprehensive, integrated and world-class healthcare services with state-of-the-art infrastructure and facilities n Seamless delivery of services at every level of care n Established brand name throughout India with a network of specialist doctors n Network
Slide 30: Max Speciality Products
Max Speciality Products www.maxindia.com 30
Slide 31: Global BOPP Industry Key Drivers
Global BOPP Industry Key Drivers n Global flexible packaging industry market size US$ 50 billion, of which BOPP Films contribute 70% n Growth of flexible packaging Industry, nearly 15% n Competitive advantage of BOPP films over other plastics and traditional products n Shift from PET to BOPP. (In In
Slide 32: Business Evolution… into Value Added Products
Max Speciality Products Business Evolution… into Value Added Products Speciality Metallised Commodity Coated Films Foils (Preferred) Films Packaging, Packaging, Packaging, Packaging, Lifestyle, End Use Industrial, Lamination, Lamination, Industrial Apparels Textiles Capacitors* Industrial, Max Speci
Slide 33: Existing Infrastructure / Operations
Max Speciality Products Existing Infrastructure / Operations n Plant location : Near Chandigarh (250km North of Delhi) n Land : 26 Acres (Additional land being acquired) n Offices : Chandigarh, Delhi, Mumbai, Kolkata, Hyderabad, Chennai n Plant Capacity : 29,000 tpa – 3 BOPP Film Lines, 3 Metallizer
Slide 34: Differentiators and Growth Strategy
Max Speciality Products Differentiators n Manufacturer/Supplier of Niche (high margin) and High Barrier Speciality polymer films n Pioneer in introduction of value added products / technology in India n International market reach with demonstrated export track record n Long term relationship with Bl
Slide 35: Max Speciality Products – Key Highlights
Max Speciality Products – Key Highlights Track Record of Strong Performance… 35
Slide 36: Neeman Medical International
Neeman Medical International www.neeman-medical.com 36
Slide 37: Indian Clinical Research Industry Key Drivers
Indian Clinical Research Industry Key Drivers n Huge Patient Population base with Therapeutic Diversity n Cost Arbitrage Need availability gap in years to come n Huge Talent Pool 2001 2005 2010 (Projected) n Data Processing Infrastructure No. of trials 142 600 6,000 for Bio-Informatics Investigators
Slide 38: Neeman Medical International CRO Business Overview
Neeman Medical International Contract Research Organization (CRO) Business Overview n Service offerings include… Project Management Site Management Data Management, includes Bio-Statistics and Report Writing Monitoring Services Clinical Trial Material Supply Chain Management Services n Con
Slide 39: Neeman – Select List of Clients
Neeman – Select List of Clients 39
Slide 40: Max HealthStaff International
Max HealthStaff International www.maxhealthstaff.com 40
Slide 41: Max HealthStaff International
Max HealthStaff International Max HealthStaff International Limited is a training and healthcare staffing company, founded on world-class quality and service excellence offering trained Indian professionals to healthcare institutions in India and abroad Big Gap in Demand/Supply of Healthcare Resourc
Slide 42: Max HealthStaff International Business Overview and Growth Strategy
Max HealthStaff International Business Overview n Annuity based revenue model with cash inflows expected for periods upto 36 months for each placed candidate n 7 Sourcing and Training centers across Delhi, Chandigarh, Kerala and Chennai n Alliance with leading healthcare staffing companies in US n 6
Slide 43: Disclaimer
Disclaimer This presentation has been prepared by Max India Limited (the “Company”). No representation or warranty, express or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information presented or contained in the presentation. The past performan
Slide 44: Jan 2008
Jan 2008 44